Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Oral Oncol. 2023 Sep;144:106438. doi: 10.1016/j.oraloncology.2023.106438. Epub 2023 Jul 10.
To identify the prognostic value of the nodal features, propose a nomogram-based N stage system and evaluate the performance of seven N stage schemes of nasopharyngeal carcinoma (NPC) patients.
Data from 1638 non-distant metastatic NPC patients were used to develop nomograms predicting 3-year and 5-year overall survival (OS) and distant metastasis-free survival (DMFS). Based on nomogram and multivariate analyses, a new N-stage scheme was proposed. The performance of the nomogram-based N staging system was assessed against five newly proposed N staging systems and the current 8th N staging system using a quantitative model to compare hazard consistency, discrimination, outcome prediction, and sample size balance. The Kaplan-Meier method with log-rank tests was used to compare survival differences.
Nomograms to predict OS and DMFS were constructed using extranodal extension infiltrating the surrounding structures (ENEmax), maximal axial diameter (MAD), large retropharyngeal lymph nodes (RLN, minimal axial diameter > 1.5 cm), multiple central nodal necrosis (CNN), and total lymph node (LN) number and level. Multivariate analysis showed the independent prognostic value of ENEmax and MAD > 3 cm for all selected survival endpoints (p < 0.05). Large RLN and lower neck involvement were independently associated with OS (p < 0.05). We proposed using a large RLN and MAD > 3 cm as N2 factors, and ENEmax and lower neck involvement as N3 factors. Among the seven N-stage schemes, our nomogram-based N scheme and ENEmax to N3 scheme (ENE3) ranked in the top two in the overall comparison with the elevated outcome predicting value (highest c-index). However, between the N0, N1, N1, and N2 subgroups, the ENE3 scheme showed no difference in OS or DMFS (p > 0.05).
The predictive model highlighted the independent prognostic value of ENEmax, cervical lymph node, MAD, and large RLN, which can be used as criteria for future N staging.
确定淋巴结特征的预后价值,提出一种基于列线图的 N 分期系统,并评估七种鼻咽癌(NPC)患者 N 分期方案的性能。
使用 1638 例无远处转移 NPC 患者的数据,建立预测 3 年和 5 年总生存率(OS)和无远处转移生存率(DMFS)的列线图。基于列线图和多变量分析,提出了一种新的 N 分期方案。使用定量模型比较危险一致性、区分度、预后预测和样本量平衡,评估列线图为基础的 N 分期系统与五种新提出的 N 分期系统和现行第 8 版 N 分期系统的性能。采用 Kaplan-Meier 法和对数秩检验比较生存差异。
使用淋巴结外侵犯周围结构(ENEmax)、最大轴向直径(MAD)、大咽后淋巴结(RLN,最小轴向直径>1.5cm)、多发中央淋巴结坏死(CNN)、总淋巴结(LN)数和水平构建预测 OS 和 DMFS 的列线图。多变量分析显示,ENEmax 和 MAD>3cm 对所有选择的生存终点均有独立的预后价值(p<0.05)。大 RLN 和低位颈淋巴结受累与 OS 独立相关(p<0.05)。我们建议将大 RLN 和 MAD>3cm 作为 N2 因素,将 ENEmax 和低位颈淋巴结受累作为 N3 因素。在七种 N 分期方案中,我们的列线图为基础的 N 分期方案和 ENEmax 到 N3 方案(ENE3)在整体比较中排名前两位,具有较高的预后预测价值(最高 c 指数)。然而,在 N0、N1、N1 和 N2 亚组之间,ENE3 方案在 OS 或 DMFS 方面无差异(p>0.05)。
预测模型突出了 ENEmax、颈淋巴结、MAD 和大 RLN 的独立预后价值,可作为未来 N 分期的标准。